日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success

CRATER肿瘤微环境促进CD8+ T细胞的激活,并与免疫治疗的成功相关。

Aya Ludin ,Georgia L Stirtz ,Asaf Tal ,Ajit J Nirmal ,Kathleen L Pfaff ,Michael Manos ,Naomi Besson ,Nebiyat Eskndir ,Billie Porter ,Stephanie M Jones ,Hannah M Faulkner ,Qiyu Gong ,Sophia Liu ,Irving Barrera ,Lijian Wu ,Cecilia Pessoa Rodrigues ,Aditi Sahu ,Elizabeth Jerison ,Joao V Alessi ,Biagio Ricciuti ,Douglas S Richardson ,Jodi D Weiss ,Hadley M Moreau ,Meredith E Stanhope ,Alexander B Afeyan ,James Sefton ,Wyatt D McCall ,Emily Formato ,Song Yang ,Yi Zhou ,David P Hoytema van Konijnenburg ,Hannah L Cole ,Miguel Cordova ,Liang Deng ,Milind Rajadhyaksha ,Stephen R Quake ,Mark M Awad ,Fei Chen ,Kai W Wucherpfennig ,Peter K Sorger ,F Stephen Hodi ,Scott J Rodig ,George F Murphy ,Leonard I Zon

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

生物标志物导向的靶向治疗联合度伐单抗治疗晚期非小细胞肺癌:一项 2 期伞状试验

Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa L Johnson, Sophie

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

MET激酶结构域中的激活点突变代表了肺癌和其他恶性肿瘤的一个独特的分子亚群,这些亚群可作为MET抑制剂的靶点。

Federica Pecci #,Seshiru Nakazawa #,Biagio Ricciuti,Guilherme Harada,Jessica K Lee,Joao V Alessi,Adriana Barrichello,Victor R Vaz,Giuseppe Lamberti,Alessandro Di Federico,Malini M Gandhi,Dimitris Gazgalis,William W Feng,Jie Jiang,Simon Baldacci,Marie-Anaïs Locquet,Felix H Gottlieb,Monica F Chen,Elinton Lee,Danielle Haradon,Anna Smokovich,Emma Voligny,Tom Nguyen,Vikas K Goel,Zachary Zimmerman,Sumandeep Atwal,Xinan Wang,Magda Bahcall,Rebecca S Heist,Sumaiya Iqbal,Nishant Gandhi,Andrew Elliott,Ari M Vanderwalde,Patrick C Ma,Balazs Halmos,Stephen V Liu,Jianwei Che,Alexa B Schrock,Alexander Drilon,Pasi A Jänne #,Mark M Awad #

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

人类癌症中致癌酪氨酸激酶融合的机制模式和临床意义

Taek-Chin Cheong #,Ahram Jang #,Qi Wang,Giulia C Leonardi,Biagio Ricciuti,Joao V Alessi,Alessandro Di Federico,Mark M Awad,Maria K Lehtinen,Marian H Harris,Roberto Chiarle

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings

新辅助阿特珠单抗联合化疗治疗可切除非小细胞肺癌:II期临床试验结果及转化研究3年临床进展

Brian S Henick ,Peter D Koch ,Justin F Gainor ,Mark M Awad ,Codruta Chiuzan ,Stephanie Izard ,Yohanna Georgis ,Samyukta Mallick ,Robert F Garofano ,Cheryl V Wong ,Anjali Saqi ,Jessica Grindheim ,Katja Schulze ,Joshua R Sonett ,Naiyer A Rizvi ,Benjamin Izar ,Alison M Taylor ,Catherine A Shu

Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden

p53 的缺失和突变异质性驱动了具有高肿瘤突变负荷的自体小鼠肺癌模型的免疫抵抗。

Mingrui Zhu ,Jiwoong Kim ,Qing Deng ,Biagio Ricciuti ,Joao V Alessi ,Buse Eglenen-Polat ,Matthew E Bender ,Hai-Cheng Huang ,Ryan R Kowash ,Ileana Cuevas ,Zachary T Bennett ,Jinming Gao ,John D Minna ,Diego H Castrillon ,Mark M Awad ,Lin Xu ,Esra A Akbay

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer

ALK肽疫苗可恢复ALK重排非小细胞肺癌的免疫原性

Ines Mota ,Enrico Patrucco ,Cristina Mastini ,Navin R Mahadevan ,Tran C Thai ,Elisa Bergaggio ,Taek-Chin Cheong ,Giulia Leonardi ,Elif Karaca-Atabay ,Marco Campisi ,Teresa Poggio ,Matteo Menotti ,Chiara Ambrogio ,Dario L Longo ,Susan Klaeger ,Hasmik Keshishian ,Zsófia M Sztupinszki ,Zoltan Szallasi ,Derin B Keskin ,Jonathan S Duke-Cohan ,Bruce Reinhold ,Steven A Carr ,Catherine J Wu ,Kelly D Moynihan ,Darrell J Irvine ,David A Barbie ,Ellis L Reinherz ,Claudia Voena ,Mark M Awad ,Rafael B Blasco ,Roberto Chiarle

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

小细胞肺癌的内在免疫原性由其细胞可塑性揭示

Navin R Mahadevan #,Erik H Knelson #,Jacquelyn O Wolff,Amir Vajdi,Maria Saigí,Marco Campisi,Deli Hong,Tran C Thai,Brandon Piel,Saemi Han,Bruce B Reinhold,Jonathan S Duke-Cohan,Michael J Poitras,Luke J Taus,Patrick H Lizotte,Andrew Portell,Victor Quadros,Alison D Santucci,Takahiko Murayama,Israel Cañadas,Shunsuke Kitajima,Aoi Akitsu,Maya Fridrikh,Hideo Watanabe,Brendan Reardon,Prafulla C Gokhale,Cloud P Paweletz,Mark M Awad,Eliezer M Van Allen,Ana Lako,Xi-Tao Wang,Benjamin Chen,Fangxin Hong,Lynette M Sholl,Michael Y Tolstorukov,Kathleen Pfaff,Pasi A Jänne,Evisa Gjini,Robin Edwards,Scott Rodig,Ellis L Reinherz,Matthew G Oser,David A Barbie

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

选择性组蛋白去乙酰化酶抑制剂 ACY-241(西他诺司他)联合纳武利尤单抗治疗晚期非小细胞肺癌:一项 Ib 期研究的结果

Mark M Awad ,Yvan Le Bruchec ,Brian Lu ,Jason Ye ,JulieAnn Miller ,Patrick H Lizotte ,Megan E Cavanaugh ,Amanda J Rode ,Calin Dan Dumitru ,Alexander Spira

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

针对晚期黑色素瘤、非小细胞肺癌或膀胱癌患者的个性化新抗原疗法联合抗 PD-1 治疗的 Ib 期试验

Patrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, Ramaswamy Govindan, Aung Naing, Nina Bhardwaj, Kim Margolin, Mark M Awad, Matthew D Hellmann, Jessica J Lin, Terence Friedlander, Meghan E Bushway, Kristen N Balogh, Tracey E Sciuto, Victoria Kohler, Samantha J Turnbull, Rana Besada, Riley R Cu